Regeneron provides update on fasinumab program

August 18, 2020

Regeneron will discontinue actively treating patients with fasinumab, which currently only involves dosing in an optional second-year extension phase of one trial. This follows a recommendation from the fasinumab program's Independent Data Monitoring Committee that the program should be terminated, based on available evidence to date. Regeneron has already obtained the core efficacy data to support potential fasinumab regulatory filings, and we will continue to gather long-term safety data, which we expect to report in 2021, along with our decision on the program. Regeneron recently provided an update on fasinumab Phase 3 safety and efficacy results in our second quarter 2020 earnings announcement.

Forward-Looking Statements and Use of Digital Media

This statement includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products and product candidates and research and clinical programs now underway or planned, including without limitation fasinumab; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron's product candidates, such as fasinumab; safety issues resulting from the administration of Regeneron's product candidates (such as fasinumab) in patients, including serious complications or side effects in connection with the use of Regeneron's product candidates in clinical trials; determinations by relevant authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's product candidates, such as fasinumab; and the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators (such as the fasinumab program) may lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission, including its Form 10-Q for the quarterly period ended June 30, 2020. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).